samedan logo

home > news > detailed info

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company


Berlin, Germany and Cairo, Egypt, May 27, 2021
: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The formation of MiGenTra accelerates ProBioGen's 2030 growth roadmap and showcases that further growth is not limited to the ongoing capacity increase but reveals one of several significant steps in the diversification of ProBioGen's business.

MiGenTra will enhance the accessibility to critical healthcare transforming medicines at affordable prices for Egypt, the Middle East and Africa (MEA) while simultaneously strengthening regional and local manufacturing capacities. The company will respond to urgent unmet medical needs, supporting efforts by the World Health Organization (WHO) and the International Finance Corporation (IFC).

MiGenTra combines the scientific and manufacturing expertise from both contributing companies, ProBioGen and Minapharm Pharmaceuticals. It is established for product development and commercialization in the field of Biosimilars, Cell and Gene Therapies (CGT) and vaccines, capitalizing on the strong development capabilities of ProBioGen and the excellent market position of Minapharm in the region.

"Healthcare is not a privilege but a human right", says Lutz Hilbrich, MD MBA and Chief Executive Officer of ProBioGen. He continues: "By creating MiGenTra we exemplify our commitment to overcome inequalities. ProBioGen has been for a while on a growth path. With the formation of MiGenTra we aim to further accelerate our growth while transforming the lives of millions in urgent medical need through state of the art medicines at affordable prices. I am honored to take on the CEO position for this newly built entity. We are committed to contributing to the transformational change across healthcare in the African continent."

Wafik Bardissi, PhD, Chairman and Chief Executive Officer of Minapharm Pharmaceuticals added: "MiGenTra marks a starting point of practice to consolidate an international platform of intelligent biopharmaceutical technologies with a longstanding regional process development and manufacturing expertise in the Middle East and Africa. Minapharm has demonstrated the feasibility of aligning economic interests and equality in access to affordable complex genetically engineered medicines. The COVID-19 pandemic has once again exposed global inequalities the world has ignored for too long. MiGenTra pledges to ensure equitable access to essential medicines, thereby contributing to the Global Health Initiative."

phone +49 (0) 30 3229 35 100
email Herbert-Bayer-Straße 8 13086 Berlin
Print this page
Send to a friend
News and Press Releases

Takara Bio Enters into a License and Supply Agreement of RetroNectin® with BioNTech Cell & Gene Therapies GmbH

Kusatsu/Shiga, Japan – June 24, 2021 – Life Science Newswire – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies GmbH ("BioNTech"), a BioNTech SE company (, Germany, under which Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin®.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research


Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement